Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PRIMO 2022 | Selecting patients for immunotherapy based on driver mutations

Paul Bunn, MD, University of Colorado Cancer Center, Aurora, CO, comments on which groups of patients with non-small cell lung cancer (NSCLC) should receive immunotherapy based their driver mutations. Whilst EGFR-mutant lung cancer will respond poorly to immunotherapy, it remains unclear whether patients with KRAS or BRAF mutations will benefit from immunotherapy before or after receiving tyrosine kinase inhibitors (TKIs) such as sotorasib, dabrafenib, and trametinib. For patients who progress from TKIs, additional questions remain over whether they should receive chemotherapy alone or with immunotherapy, with the results from the Phase III IMpower150 (NCT02366143) suggesting the latter. This interview took place at the 7th Annual Practical Recommendations in Immuno and Molecular Oncology Meeting (PRIMO 2022).

Disclosures

Dr Bunn reports is a member of the DMC committees of Merck, and BMS; has received consulting fees from AZ, Lilly, Ascentage, CStone, viecure, and Imidex; and is on the Board of Directors of Verastem.